Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Cytek Biosciences (CTKB) Acquisitions (2023 - 2024)

Cytek Biosciences filings provide 2 years of Acquisitions readings, the most recent being $471000.0 for Q4 2024.

On a quarterly basis, Acquisitions changed N/A to $471000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $471000.0, a 98.95% decrease, with the full-year FY2024 number at $471000.0, down 98.95% from a year prior.
Acquisitions hit $471000.0 in Q4 2024 for Cytek Biosciences, up from $1000.0 in the prior quarter.
In the past five years, Acquisitions ranged from a high of $44.9 million in Q1 2023 to a low of $1000.0 in Q3 2023.